Press Releases
// Aug 13, 2025
ElevateBio BaseCamp Achieves ICMC™ Certification for Commercial Cell and Gene Therapy Manufacturing Capabilities
// May 12, 2025
ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
// Apr 28, 2025
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
// Apr 28, 2025
ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors
// Mar 10, 2025
ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI
// Feb 24, 2025
ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease
// Jan 09, 2025
ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
// Nov 04, 2024
ElevateBio Appoints Amy Pooler Ph.D., as Senior Vice President, Research and Development
// Oct 16, 2024
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential
// May 14, 2024
ElevateBio Announces New U.S. Patents for Lead Life Edit CRISPR Systems and Adenine Deaminases Enabling Advanced Gene Editing Techniques
// Apr 22, 2024
